ERBB2 and breast cancer: In particular, it was shown that its use in a subpopulation of breast cancer cells suppressed their growth and decreased the ability of these cells to form tumours in mice [77]; its combination with trastuzumab leads to a reduction of cancer-initiating cell population in Her2-amplified breast cancer cells [78].